| 5.6 -1.03 (-15.54%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.8 | 1-year : | 10.28 |
| Resists | First : | 7.53 | Second : | 8.8 |
| Pivot price | 3.61  |
|||
| Supports | First : | 3.69 | Second : | 1.32 |
| MAs | MA(5) : | 5.42 |
MA(20) : | 3.1 |
| MA(100) : | 3.37 |
MA(250) : | 5.54 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 77.4 |
D(3) : | 76.3 |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 21 | Low : | 1.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ACXP ] has closed below upper band by 23.6%. Bollinger Bands are 302.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.61 - 6.64 | 6.64 - 6.66 |
| Low: | 5.31 - 5.35 | 5.35 - 5.37 |
| Close: | 5.55 - 5.6 | 5.6 - 5.64 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Thu, 19 Mar 2026
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Thu, 19 Mar 2026
Can Acurx Pharmaceuticals (ACXP) Surge by 226.3% to Meet the Target Set by Wall Street Analysts? - Bitget
Thu, 19 Mar 2026
Can Acurx Pharmaceuticals (ACXP) Rise by 226.3% to Meet the Target Set by Wall Street Experts? - Bitget
Thu, 19 Mar 2026
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Thu, 19 Mar 2026
ACXP Should I Buy - Intellectia AI
Tue, 17 Mar 2026
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 8.7 (%) |
| Shares Short | 74 (K) |
| Shares Short P.Month | 80 (K) |
| EPS | -8.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.7 % |
| Return on Equity (ttm) | -291.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.69 |
| PEG Ratio | 0 |
| Price to Book value | 2.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|